© 2023 Osmol Therapeutics. All rights reserved.
designed and managed by Body1
© 2023 Osmol Therapeutics. All rights reserved.
designed and managed by Body1
CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) affects hundreds of thousands of cancer patients every year, and can compromise optimum chemotherapy dosing. There are no effective treatments for CIPN, a condition which can diminish quality of life and lead to lifelong disability. Taxane-based chemotherapy agents used to treat breast cancer patients are particularly problematic where CIPN occurrence is as high as 80%.1
Osmol is Developing a Treatment to Prevent CIPN Before it Starts
Data from preclinical studies conducted by Osmol show that pretreatment with OSM-0205 prevents neuronal damage from taxanes in mice by preventing the off-target intracellular calcium surge caused by these chemotherapy agents. It is hypothesized that OSM-0205 in patients will protect neurons from damage leading to a reduction of CIPN. This prevention of CIPN will allow more optimal chemotherapy dosing.
CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) affects hundreds of thousands of cancer patients every year, and can compromise optimum chemotherapy dosing. There are no effective treatments for CIPN, a condition which can diminish quality of life and lead to lifelong disability. Taxane-based chemotherapy agents used to treat breast cancer patients are particularly problematic where CIPN occurrence is as high as 80%.1
Osmol is Developing a Treatment to Prevent CIPN Before it Starts
Data from preclinical studies conducted by Osmol show that pretreatment with OSM-0205 prevents neuronal damage from taxanes in mice by preventing the off-target intracellular calcium surge caused by these chemotherapy agents. It is hypothesized that OSM-0205 in patients will protect neurons from damage leading to a reduction of CIPN. This prevention of CIPN will allow more optimal chemotherapy dosing.